135 related articles for article (PubMed ID: 37337131)
21. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
[TBL] [Abstract][Full Text] [Related]
22. Increased serum autotaxin levels in hepatocellular carcinoma patients were caused by background liver fibrosis but not by carcinoma.
Kondo M; Ishizawa T; Enooku K; Tokuhara Y; Ohkawa R; Uranbileg B; Nakagawa H; Tateishi R; Yoshida H; Kokudo N; Koike K; Yatomi Y; Ikeda H
Clin Chim Acta; 2014 Jun; 433():128-34. PubMed ID: 24642343
[TBL] [Abstract][Full Text] [Related]
23. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.
Hao YL; Bian ZL; Ju LL; Liu Y; Qin G
Dig Dis Sci; 2020 Feb; 65(2):470-479. PubMed ID: 31377883
[TBL] [Abstract][Full Text] [Related]
24. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
[TBL] [Abstract][Full Text] [Related]
25. Expression of autotaxin mRNA in human hepatocellular carcinoma.
Zhang G; Zhao Z; Xu S; Ni L; Wang X
Chin Med J (Engl); 1999 Apr; 112(4):330-2. PubMed ID: 11593532
[TBL] [Abstract][Full Text] [Related]
26. Toward precision medicine in primary biliary cholangitis.
Carbone M; Ronca V; Bruno S; Invernizzi P; Mells GF
Dig Liver Dis; 2016 Aug; 48(8):843-50. PubMed ID: 27324985
[TBL] [Abstract][Full Text] [Related]
27. Ursodeoxycholic acid influences the expression of p27kip1 but not FoxO1 in patients with non-cirrhotic primary biliary cirrhosis.
Milkiewicz M; Kopycińska J; Kempińska-Podhorodecka A; Haas T; Bogdanos DP; Elias E; Milkiewicz P
J Immunol Res; 2014; 2014():921285. PubMed ID: 24741631
[TBL] [Abstract][Full Text] [Related]
28. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
Hirschfield GM; Dyson JK; Alexander GJM; Chapman MH; Collier J; Hübscher S; Patanwala I; Pereira SP; Thain C; Thorburn D; Tiniakos D; Walmsley M; Webster G; Jones DEJ
Gut; 2018 Sep; 67(9):1568-1594. PubMed ID: 29593060
[TBL] [Abstract][Full Text] [Related]
29. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
Hirschfield GM; Beuers U; Kupcinskas L; Ott P; Bergquist A; Färkkilä M; Manns MP; Parés A; Spengler U; Stiess M; Greinwald R; Pröls M; Wendum D; Drebber U; Poupon R
J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
[TBL] [Abstract][Full Text] [Related]
30. Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy.
Vespasiani-Gentilucci U; Rosina F; Pace-Palitti V; Sacco R; Pellicelli A; Chessa L; De Vincentis A; Barlattani M; Barlattani A; Feletti V; Mussetto A; Zolfino T; Russello M; Cozzolongo R; Garrucciu G; Niro G; Bacca D; Bertino G; Claar E; Ascione A; D'Adamo G; Adinolfi LE; Scifo G; Izzi A;
Scand J Gastroenterol; 2019 Oct; 54(10):1274-1282. PubMed ID: 31564176
[No Abstract] [Full Text] [Related]
31. Serum Autotaxin is a Marker of the Severity of Liver Injury and Overall Survival in Patients with Cholestatic Liver Diseases.
Wunsch E; Krawczyk M; Milkiewicz M; Trottier J; Barbier O; Neurath MF; Lammert F; Kremer AE; Milkiewicz P
Sci Rep; 2016 Aug; 6():30847. PubMed ID: 27506882
[TBL] [Abstract][Full Text] [Related]
32. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
33. The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study.
Jones DEJ; Wetten A; Barron-Millar B; Ogle L; Mells G; Flack S; Sandford R; Kirby J; Palmer J; Brotherston S; Jopson L; Brain J; Smith GR; Rushton S; Jones R; Rushbrook S; Thorburn D; Ryder SD; Hirschfield G; ; Dyson JK
EBioMedicine; 2022 Jun; 80():104068. PubMed ID: 35609437
[TBL] [Abstract][Full Text] [Related]
34. Male Sex Is Associated With Higher Rates of Liver-Related Mortality in Primary Biliary Cholangitis and Cirrhosis.
John BV; Aitcheson G; Schwartz KB; Khakoo NS; Dahman B; Deng Y; Goldberg D; Martin P; Taddei TH; Levy C; Kaplan DE
Hepatology; 2021 Aug; 74(2):879-891. PubMed ID: 33636012
[TBL] [Abstract][Full Text] [Related]
35. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China.
Chen S; Duan W; Li M; Li S; Lv T; Tian Q; Wang Q; Wu X; Zhao X; Wang X; Wang Y; Kong Y; Ma H; Ou X; You H; Jia J
J Gastroenterol Hepatol; 2019 Jul; 34(7):1236-1241. PubMed ID: 30365184
[TBL] [Abstract][Full Text] [Related]
36. Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients.
Weinmann A; Sattler T; Unold HP; Grambihler A; Teufel A; Koch S; Schuchmann M; Biesterfeld S; Wörns MA; Galle PR; Schulze-Bergkamen H
J Clin Gastroenterol; 2015; 49(5):438-47. PubMed ID: 25014239
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes and sick leave in relation to UDCA treatment in Swedish patients with primary biliary cholangitis.
Henriksson I; Udumyan R; Nilsson E; Önnerhag K; Rorsman F; Werner M; Marschall HU; Wahlin S; Nyhlin N;
Scand J Gastroenterol; 2023 Jan; 58(1):70-75. PubMed ID: 35993428
[TBL] [Abstract][Full Text] [Related]
38. Clinical Outcomes and Validation of Ursodeoxycholic Acid Response Scores in Patients with Korean Primary Biliary Cholangitis: A Multicenter Cohort Study.
Chang JI; Kim JH; Sinn DH; Cho JY; Kim KM; Oh JH; Park Y; Sohn W; Goh MJ; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Gut Liver; 2023 Jul; 17(4):620-628. PubMed ID: 36999383
[TBL] [Abstract][Full Text] [Related]
39. Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis.
Ni P; Men R; Shen M; Wang T; Huang C; Fan X; Yang L
Can J Gastroenterol Hepatol; 2019; 2019():7396870. PubMed ID: 31275901
[TBL] [Abstract][Full Text] [Related]
40. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.
Corpechot C; Carrat F; Bonnand AM; Poupon RE; Poupon R
Hepatology; 2000 Dec; 32(6):1196-9. PubMed ID: 11093724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
